Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
6.2 Novo Nordisk + Septerna (May 2025, up to $2.2B) Novo's second major triple-agonist transaction was a broader small-molecule GPCR collaboration with Septerna announced May 2025: up to $2.2 billion total deal value, $200 million+ upfront, covering four oral small-molecule GPCR programs
The retrieval period spans from the inception of the data bases up to February 2024
White fish varieties are particularly well-tolerated by patients with nausea
The medication works by mimicking the action of naturally occurring GLP-1, a hormone released from the intestine in response to food intake
The Neurovascular Unit as a Metabolic and Structural Barrier The BBB functions essentially as a highly specialized metabolic organ
IPL photofacial, because sun damage makes laxity look worse Post-weight-loss skin can look more aged when pigment and redness sit on top of thinner, less supported tissue
US$ 29.37
US$ 25.02
US$ 24.42
US$ 25.95
US$ 22.38
US$ 21.43
US$ 20.96
